Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.

NCT04458597 | Completed

• 1 other identifier: SPARTACUS
• Study Type: interventional
• Target: 23
• Locations: 1 country
• Sites: 1

Brief Summary

Advanced technology has enabled radiation oncologists to more accurately and precisely target radiation to areas at risk while maximally sparing healthy tissue. Furthermore, there is growing evidence demonstrating both safety and efficacy for SBRT. We propose that these advantages are translatable to the adjuvant treatment of endometrial cancer. We submit that a prescription dose of 30 Gy in 5 fractions, which equates to a 2 Gy equivalent dose (i.e an EQD2) (α/β = 10 Gy) of 48 Gy, compares favorably to the EQD2 delivered standardly for adjuvant treatment (44.25 Gy via 45Gy/25Fx; 50 Gy at vaginal surface for vault brachytherapy) and therefore should be effective and safe dose in the adjuvant setting. Through precision delivery and careful dosimetry the treatment should be safe and well tolerated with minimal impact on patient quality of life.

Conditions

Endometrioid Adenocarcinoma; Serous Carcinoma; Clear Cell Carcinoma; Carcinosarcoma; Dedifferentiated Carcinoma

Outcome Measures

Primary Outcomes (1)

• Assess the acute urinary and bowel toxicities

  Acute urinary and bowel toxicities associated with adjuvant SBRT treatment in the setting of high-risk endometrial cancer will be assessed using the Common Terminology Criteria for Adverse Events.

  Baseline to 2 years post-treatment.

Interventions

Image-guided adjuvant pelvic radiotherapy RADIATION

Image-guided adjuvant pelvic radiotherapy delivered at an SBRT prescription dose of 30 Gy in 5 fractions if feasible, well-tolerated and effective for the adjuvant treatment of high-risk endometrial cancer.

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients, who have undergone hysterectomy for curative intent, with histologically confirmed endometrioid adenocarcinoma, serous or clear cell carcinoma, or carcinosarcoma or dedifferentiated carcinoma
• Patient is a candidate for adjuvant pelvic radiation (+/- vault brachytherapy), meeting one of the following conditions:
• High grade histology OR
• Outer-half myometrial invasion and FIGO grade 1-2 OR
• FIGO stage II - IIIC1 (all gross nodal disease must be resected)
• Patient is willing and able to give informed consent to participate in this clinical trial.
• Age ≥18 years.
• Patients who are to receive adjuvant systemic therapy in addition to pelvic radiotherapy will be eligible provided that there is at minimum a 3-week interval between any radiation treatment and chemotherapy treatments. Adjuvant systemic therapy may be given before or after radiation treatment.
• Patient must be willing and able to complete the QLQ-C30 questionnaire with EN-24 companion as described in the study protocol.
• Primary language of the patient must be English or, if a patient's primary language is not English, they are still able to participate provided the QLQ-C30 and EN-24 is available in their primary language.

You may not qualify if:

• Patient has had prior pelvic radiotherapy.
• Patient has received neo-adjuvant systemic therapy
• Patient has a contraindication to pelvic radiotherapy, such as but not limited to a connective tissue disease or inflammatory bowel disease.
• Patient has a contraindication to iodinated CT contrast.
• Patient has a hip prosthesis.

Sponsors & Collaborators

• London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's: lead

Study Sites (1)

London Regional Cancer Program

London, Ontario, N6A 5W9, Canada

Location

MeSH Terms

Conditions

Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Adenocarcinoma, Clear Cell; Carcinosarcoma

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Endometrial Neoplasms; Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Ovarian Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases; Cystadenocarcinoma; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Complex and Mixed; Sarcoma; Neoplasms, Connective and Soft Tissue

Study Officials

• David D'Souza, M.D.

  London Regional Cancer Program

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 23, 2020
• First Posted: July 7, 2020
• Study Start: August 26, 2020
• Primary Completion: May 2, 2024
• Study Completion: May 14, 2024
• Last Updated: August 1, 2025

Record last verified: 2025-07

Locations

CA (1)